Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Laura Huppert, MD, BA
Summary
This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.
Description
PRIMARY OBJECTIVES: I. To evaluate the objective response rate (ORR) of participants with HER2-low locally advanced unresectable/metastatic breast cancer on ARX788 monotherapy. SECONDARY OBJECTIVES: I. To evaluate the efficacy of ARX788 monotherapy in participants with HER2-low locally advanced unresectable or metastatic breast cancer (MBC) as measured by duration of response (DOR), best overall response (BOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). II. To evaluate the safety of ARX788 monotherapy in participants with HER2-low locally advanc…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female participants age 18 years or greater with ability to provide written informed consent for the study. * Eastern Cooperative Oncology Group (ECOG) score of 0-2. * Estimated life expectancy of at least at 6 months per investigator assessment. * Ability to understand and the willingness to sign a written informed consent document. * Pathologically documented HER2-low locally advanced unresectable or metastatic breast cancer (MBC). NOTE: human epidermal growth factor receptor 2 (HER2)-low status determined by HER2 immunohistochemistry (IHC) 1+ or 2+ and no evid…
Interventions
- DrugARX788
Given IV
- ProcedureComputed Tomography (CT)
Undergo CT or Positron Emission Tomography(PET)/CT
- ProcedureBiospecimen Collection
Undergo collection of blood samples
- DrugAmiloride
Ophthalmologic drops given topically to participants for an eye toxicity substudy
Location
- University of California, San FranciscoSan Francisco, California